Floatz logo

Buqitongluo Granule

Stroke, Ischemic

Dongzhimen Hospital, BeijingPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

211 Active assets in the Stroke, Ischemic cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
3-N-BUTYLPHTHALIDE
Nanfang Hospital, Southern Medical University
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

Buqitongluo Granule is also rated in:

coronary artery disorderDormant
CCC
Indicative ·
53 / 100
View asset →
diabetic neuropathyDormant
CCC
Indicative ·
53 / 100
View asset →
coronary artery disorderDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →